Related references
Note: Only part of the references are listed.Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms
Ingo K. Mellinghoff et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2022)
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Nimish A. Mohile et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Michael Weller et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2021)
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Martin J. van den Bent et al.
LANCET ONCOLOGY (2021)
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Michael Platten et al.
NATURE (2021)
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Ingo K. Mellinghoff et al.
CLINICAL CANCER RESEARCH (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2021)
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Daniel J. Brat et al.
ACTA NEUROPATHOLOGICA (2020)
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma
Annette M. Molinaro et al.
JAMA ONCOLOGY (2020)
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2020)
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma
Ingo K. Mellinghoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
Erica H. Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Central Nervous System Cancers Version 3.2020
Louis Burt Nabors et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas
Romain Appay et al.
NEURO-ONCOLOGY (2019)
Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma
Shervin Tabrizi et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma
Tejus A. Bale et al.
NEURO-ONCOLOGY (2019)
Management of low-grade glioma: a systematic review and meta-analysis
Timothy J. Brown et al.
NEURO-ONCOLOGY PRACTICE (2019)
Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience
David Capper et al.
ACTA NEUROPATHOLOGICA (2018)
DNA methylation-based classification of central nervous system tumours
David Capper et al.
NATURE (2018)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Lukas Bunse et al.
NATURE MEDICINE (2018)
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
Samuel K. McBrayer et al.
CELL (2018)
Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2017)
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J. van den Bent et al.
LANCET (2017)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Jan C. Buckner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II-III) Astrocytomas
Gerald F. Reis et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2015)
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
J. Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations
Xiao-Yang Liu et al.
ACTA NEUROPATHOLOGICA (2012)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults:: the EORTC 22845 randomised trial
MJ van den Bent et al.
LANCET (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prospective Randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study
E Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
